In vitro susceptibility of urogenital Chlamydia trachomatis strains in a country with high azithromycin consumption rate

Folia Microbiologica

Volumn 58, Issue 5, 2013, Pages 361-365

  Ljubin Sternak, Suncanica ^a,b   Mestrovic, Tomislav ^c   Vilibic Cavlek, Tatjana ^a,b   Mlinaric Galinovic, Gordana ^a,b   Sviben, Mario ^a,b   Markotic, Alemka ^b   Skerk, Visnja ^b  

^a CROATIAN NATIONAL INSTITUTE OF PUBLIC HEALTH   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c Polyclinic for Medical Microbiology and Parasitology Dr Zora Profozic   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

CHLAMYDIA TRACHOMATIS;

EID: 84881027067     PISSN: 00155632     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12223-012-0218-2     Document Type: Article

References (20)

1. Agacfidan A, Moncada J, Schachter J (1993) In vitro activity of azithromycin (CP-62, 993) against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother 37: 1746-1748.
2. Bhengraj AR, Vardhan H, Srivastava P, Salhan S, Mittal A (2010) Decreased susceptibility to azithromycin and doxycycline in clinical isolates of Chlamydia trachomatis obtained from recurrently infected female patients in India. Chemotherapy 56: 371-377.
3. Binet R, Bowlin AK, Maurelli AT, Rank RG (2010) Impact of azithromycin resistance mutations on the virulence and fitness of Chlamydia caviae in guinea pigs. Antimicrob Agents Chemother 54: 1094-1101.
4. Biros E, Bodnár J, Biros I, Birosová E, Mojzis J, Hrivnák M, Klimcáková L, Findlay I, Mirossay A, Mirossay L (2007) Nucleic acid amplification technique for detection of Chlamydia trachomatis infection from clinical urogenital swabs. Folia Microbiol (Praha) 52: 437-442.
5. Centers for Disease Control and Prevention (2009) Sexually transmitted disease surveillance. Department of Health and Human Services, Atlanta.
6. Donati M, Di Francesco A, D'antuono A, Delucca F, Shurdhi A, Moroni A, Baldelli R, Cevenini R (2010) In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K. Antimicrob Agents Chemother 54: 5379-5380.
7. Dugan J, Rockey DD, Jones L, Andersen AA (2004) Tetracycline resistance in Chlamydia suis mediated by genomic islands inserted into the chlamydial inv-like gene. Antimicrob Agents Chemother 48: 3989-3995.
8. Hiršl-Hećej V, Pustišek N, Sikanić-Dugić N, Domljan LM, Kani D (2006) Prevalence of chlamydial genital infection and associated risk factors in adolescent females at an urban reproductive health care center in Croatia. Collegium Anthropologicum 30: 131-137.
9. Hong KC, Schachter J, Moncada J, Zhou Z, House J, Lietman TM (2009) Lack of macrolide resistance in Chlamydia trachomatis after mass azithromycin distributions for trachoma. Emerg Infect Dis 15: 1088-1090.
10. Jones RB, van Der Pol B, Martin DH, Shepard MK (1990) Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics. J Infect Dis 162: 1309-1315.
11. Lefèvre JC, Lépargneur JP (1998) Comparative in vitro susceptibility of a tetracycline-resistant Chlamydia trachomatis strain isolated in Toulouse (France). Sex Transm Dis 25: 350-352.
12. Ljubin-Sternak S, Kružić V, Vilibić-Čavlek T, Škerk V (2006) Chlamydia trachomatis infection in Croatian symptomatic and asymptomatic men. J Men's Health Gend 3: 80-81.
13. Ljubin-Sternak S, Škerk V (2010) Determining antimicrobial resistance to Chlamydia trachomatis and applying present findings in daily practice. Med Glas Ljek Komore Zenicko-Doboj Kantona 7: 26-31.
14. Samra Z, Rosenberga S, Sofferb Y, Danc M (2001) In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines. Diagn Microbiol Infect Dis 39: 177-179.
15. Škerk V, Krhen I, Lisić M, Begovac J, Roglić S, Škerk V, Sternak SL, Banaszak A, Strugar-Šuica J, Vuković J (2004) Comparative randomized pilot study of azithromycin and doxycycline efficacy in the treatment of prostate infection caused by Chlamydia trachomatis. Int J Antimicrob Agents 24: 188-191.
16. Škerk V, Markovinović L, Zekan S, Jakšić J, Židovec Lepej S, Markotić A, Škerk V, Radošević V, Cvitković L, Begovac J (2009) The significance of Chlamydia trachomatis in urethritis and prostatitis-differences in therapeutic approach-Croatian experience. J Chemother 21: 63-67.
17. Solomon AW, Mohammed Z, Massae PA, Shao JF, Foster A, Mabey DC, Peeling RW (2005) Impact of mass distribution of azithromycin on the antibiotic susceptibilities of ocular Chlamydia trachomatis. Antimicrob Agents Chemother 49: 4804-4806.
18. Somani J, Bhullar VB, Workowski KA, Farshy CE, Black CM (2000) Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis 181: 1421-1427.
19. Suchland RJ, Geisler WM, Stamm WE (2003) Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp. Antimicrob Agents Chemother 47: 636-642.
20. Vojvodić Ž (2010) Antimicrobial use and indication-based prescribing among general practitioners in Eastern Croatia: comparison with data from the European Surveillance of Antimicrobial Consumption project. Croat Med J 51: 524-533.